Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer

Clinical Cancer Research

Volumn 15, Issue 20, 2009, Pages 6398-6403

  Hermans, Karin G ^a   Boormans, Joost L ^b   Gasi, Delila ^a   Van Leenders, Geert J H L ^a   Jenster, Guido ^b   Verhagen, Paul C M S ^b   Trapman, Jan ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; PROSTATE SPECIFIC ANTIGEN; TRANSCRIPTION FACTOR ERG;

ARTICLE; CANCER CELL CULTURE; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE COURSE; EXON; GENE; GENE EXPRESSION; GENE FUSION; HUMAN; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; TMPRSS2 GENE; TUMOR XENOGRAFT; WILD TYPE;

CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; EXONS; HUMANS; MALE; ONCOGENE PROTEINS, FUSION; PROGNOSIS; PROSTATIC NEOPLASMS;

EID: 70350231922     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-1176     Document Type: Article

References (20)

1. Attard G, Clark J, Ambroisine L, et al. Heterogeneity and clinical significance of ETV1 translocations in human prostate cancer. Br J Cancer 2008;99:314-320
2. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2:ETV5 and SLC45A3: ETV5 gene fusions in prostate cancer. Cancer Res 2008;68:73-80.
3. Hermans KG, Bressers AA, van der Korput HA, Dits NF, Jenster G, Trapman J. Two unique novel prostate-specific and androgen-regulated fusion partners of ETV4 in prostate cancer. Cancer Res 2008;68:3094-3098
4. Hermans KG, van der Korput HA, van Marion R, et al. Truncated ETV1, fused tonovel tissue-specific genes, and full length ETV1 in prostate cancer. Cancer Res 2008;68:7541-7549
5. Tomlins SA, Laxman B, Dhanasekaran SM, et al. Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature 2007;448:595-599 (Pubitemid 47206938)
6. Tomlins SA, Mehra R, Rhodes DR, et al. TMPRSS2:ETV4 gene fusions define a third molecular subtype of prostate cancer. Cancer Res 2006;66:3396-3400
7. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310:644-648 (Pubitemid 41528150)
8. Attard G, Clark J, Ambroisine L, et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer. Oncogene 2008;27:253-263
9. Demichelis F, Fall K, Perner S, et al. TMPRSS2: ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596-4599 (Pubitemid 47037039)
10. Nam RK, Sugar L, Yang W, et al. Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer. Br J Cancer 2007;97:1690-1695 (Pubitemid 350249347)
11. Perner S, Mosquera JM, Demichelis F, et al. TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol 2007;31:882-888 (Pubitemid 47165141)
12. Wang J, Cai Y, Ren C, Ittmann M. Expression of variant TMPRSS2/ERG fusion messenger RNAs is associated with aggressive prostate cancer. Cancer Res 2006;66:8347-8351 (Pubitemid 44449142)
13. Gopalan A, Leversha MA, Satagopan JM, Zhou Q, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009;69:1400-1406
14. Lapointe J, Kim YH, Miller MA, et al. A variant TMPRSS2 isoform and ERG fusion product in prostate cancer with implications for molecular diagnosis. Mod Pathol 2007;20:467-473 (Pubitemid 46482370)
15. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene 2005;24:3847-3852 (Pubitemid 40826884)
16. Saramaki OR, Harjula AE, Martikainen PM, Vessella RL, Tammela TL, Visakorpi T. TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008;14:3395-3400
17. Hermans KG, van Marion R, van Dekken H, Jenster G, van Weerden WM, Trapman J. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgendependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 2006;66:10658-10663 (Pubitemid 44876959)
18. van Weerden WM, de Ridder CM, Verdaasdonk CL, et al. Development of seven new human prostate tumor xenograft models and their histopathological characterization. Am J Pathol 1996; 149:1055-1062
19. Landry JR, Mager DL, Wilhelm BT. Complex controls: the role of alternative promoters in mammalian genomes. Trends Genet 2003;19: 640-648
20. Gerlo S, Davis JR, Mager DL, Kooijman R. Prolactin in man: a tale of two promoters. Bioessays 2006;28:1051-1055 (Pubitemid 44570454)